started · updated
Moderna's mRNA flu vaccine mFlusiva arrives in U.S. pharmacies
Moderna’s mFlusiva, the first influenza vaccine utilizing messenger RNA (mRNA) technology, has begun arriving at U.S. pharmacies such as CVS. The FDA approved the vaccine for adults aged 50 and older, providing standard approval for those aged 50 to 64 and accelerated approval for those 65 and older, pending additional clinical trials.
Unlike traditional egg-based vaccines, mFlusiva uses genetic instructions to train the immune system. This technology allows for a faster production timeline of two to three months, compared to the six months required for conventional formulas.
However, a reanalysis of FDA clinical data published by researchers including Dr. Peter McCullough and Nicolas Hulscher has raised concerns. The authors claim the vaccine shows low efficacy in preventing hospitalizations and carries a higher risk of adverse events and death compared to non-mRNA standard-dose vaccines. They have urged U.S. Health Secretary Robert F. Kennedy Jr. to withdraw the product.
Separately, health experts continue to emphasize the importance of pediatric immunization. The Indonesian Pediatric Society recommends annual flu shots for children starting at six months of age to mitigate high risks of symptomatic infection in young populations.
Entities
CVS · FDA · Food and Drug Administration · Moderna · Peter McCullough · Robert F. Kennedy Jr. · Walgreens · mFLUSIVA
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] mFlusiva can be manufactured in two to three months, compared to approximately six months for traditional vaccines. www.cubaheadlines.com · www.directoriocubano.info
- [● 3 SOURCES] The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults aged 50 and older. www.cubaheadlines.com · www.directoriocubano.info · www.news-medical.net
- [DISPUTED] A reanalysis of FDA clinical data suggests the mRNA vaccine has low efficacy in preventing hospitalization and a higher risk of adverse events compared to standard vaccines. activistpost.com
- [○ 1 SOURCE] The Indonesian Pediatric Society recommends annual flu vaccinations for children starting at six months of age. world-today-journal.com